share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144：擬議出售證券
美股SEC公告 ·  09/04 04:32
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 09/03/2024, as per the latest filing. These shares, originally acquired on 09/01/2016 as founder's shares in compensation for services, are valued at an aggregate market price of $71,717.45. This planned transaction follows a series of sales over the past three months, where Borgeson sold a total of 68,682 Class A shares, amounting to gross proceeds of $545,960.29.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 09/03/2024, as per the latest filing. These shares, originally acquired on 09/01/2016 as founder's shares in compensation for services, are valued at an aggregate market price of $71,717.45. This planned transaction follows a series of sales over the past three months, where Borgeson sold a total of 68,682 Class A shares, amounting to gross proceeds of $545,960.29.
Recursion Pharmaceuticals, Inc.董事Blake Borgeson計劃於2024年09/03出售公司的11,447股A類股份，根據最新提交的文件。這些股份最初是作爲創始人股份在2016年09/01獲得的，作爲對服務的補償，市值達71717.45美元。這一計劃中的交易是在過去三個月中一系列銷售行爲之後進行的，Borgeson共出售了68,682股A類股份，總收益達到545,960.29美元。
Recursion Pharmaceuticals, Inc.董事Blake Borgeson計劃於2024年09/03出售公司的11,447股A類股份，根據最新提交的文件。這些股份最初是作爲創始人股份在2016年09/01獲得的，作爲對服務的補償，市值達71717.45美元。這一計劃中的交易是在過去三個月中一系列銷售行爲之後進行的，Borgeson共出售了68,682股A類股份，總收益達到545,960.29美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。